Selected article for: "open label and treatment time symptom"

Author: Hu, Ke; Guan, Wei-Jie; Bi, Ying; Zhang, Wei; Li, Lanjuan; Zhang, Boli; Liu, Qingquan; Song, Yuanlin; Li, Xingwang; Duan, Zhongping; Zheng, Qingshan; Yang, Zifeng; Liang, Jingyi; Han, Mingfeng; Ruan, Lianguo; Wu, Chaomin; Zhang, Yunting; Jia, Zhen-Hua; Zhong, Nan-Shan; Guan, Wei-jie; Jia, Zhen-hua; Zhong, Nan-shan
Title: Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.
  • Cord-id: eb4z3u66
  • Document date: 2020_5_16
  • ID: eb4z3u66
    Snippet: BACKGROUND Coronavirus disease 2019 (Covid-19) has resulted in a global outbreak. Few existing targeted medications are available. Lianhuaqingwen (LH) capsule, a repurposed marketed Chinese herb product, has been proven effective for influenza. PURPOSE To determine the safety and efficacy of LH capsule in patients with Covid-19. METHODS We did a prospective multicenter open-label randomized controlled trial on LH capsule in confirmed cases with Covid-19. Patients were randomized to receive usual
    Document: BACKGROUND Coronavirus disease 2019 (Covid-19) has resulted in a global outbreak. Few existing targeted medications are available. Lianhuaqingwen (LH) capsule, a repurposed marketed Chinese herb product, has been proven effective for influenza. PURPOSE To determine the safety and efficacy of LH capsule in patients with Covid-19. METHODS We did a prospective multicenter open-label randomized controlled trial on LH capsule in confirmed cases with Covid-19. Patients were randomized to receive usual treatment alone or in combination with LH capsules (4 capsules, thrice daily) for 14 days. The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery. RESULTS We included 284 patients (142 each in treatment and control group) in the full-analysis set. The recovery rate was significantly higher in treatment group as compared with control group (91.5% vs. 82.4%, p = 0.022). The median time to symptom recovery was markedly shorter in treatment group (median: 7 vs. 10 days, p < 0.001). Time to recovery of fever (2 vs. 3 days), fatigue (3 vs. 6 days) and coughing (7 vs. 10 days) was also significantly shorter in treatment group (all p < 0.001). The rate of improvement in chest computed tomographic manifestations (83.8% vs. 64.1%, p < 0.001) and clinical cure (78.9% vs. 66.2%, p = 0.017) was also higher in treatment group. However, both groups did not differ in the rate of conversion to severe cases or viral assay findings (both p > 0.05). No serious adverse events were reported. CONCLUSION In light of the safety and effectiveness profiles, LH capsules could be considered to ameliorate clinical symptoms of Covid-19.

    Search related documents:
    Co phrase search for related documents
    • acid assay and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acid assay and acute respiratory tract: 1
    • acquisition contribute and acute respiratory: 1
    • acquisition contribute and lung injury: 1
    • acute respiratory and long history: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lung injury ameliorate: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory and macrophage chemokine: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and long history: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung injury ameliorate: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and macrophage chemokine: 1, 2, 3, 4, 5
    • acute respiratory tract and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • long history and lung injury: 1, 2
    • lonicera japonica and lung injury: 1
    • lung injury and macrophage chemokine: 1, 2